ctDNA detection

DIAGNOSTIC_TEST6 trials

Sponsors

Sun Yat-sen University, Fang Wu, Peking University, Shanghai Zhongshan Hospital, Swiss Cancer Institute

Conditions

Advanced Lung Non-Small Cell CarcinomaBreast CancerEvaluation of Tumor Resectability Shall be Made in Consensus at Multidisciplinary Meetings, According to NCCN Guideline Version 1.2022 Pancreatic AdenocarcinomaGastric CancerHER2 Positive Advanced Gastric CancerHigh Grade Serous Ovarian CancerNon Small Cell Lung CancerNon-hodgkin Lymphoma, B Cell

Unknown Phase

ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS

CompletedNCT03172156

Sun Yat-sen UniversityNon-small Cell Lung Cancer Stage I

Start: 2017-07-01End: 2020-02-01Updated: 2024-09-04

ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC

Active, not recruitingNCT05198154

Fang WuAdvanced Lung Non-Small Cell Carcinoma

Start: 2022-01-24End: 2029-11-30Target: 100Updated: 2026-08-31

Dynamic Multiomics Evaluation of Anti-HER2 and Immunotherapy in HER2 Positive Gastric Cancer

Peking UniversityHER2 Positive Advanced Gastric Cancer

Start: 2019-01-01End: 2025-01-01Target: 100Updated: 2022-04-27

Application of ctDNA in Evaluation of Neoadjuvant Chemotherapy Efficacy and Exploration of Chemoresistance Mechanisms in Pancreatic Cancer

Not yet recruitingNCT05848154

Shanghai Zhongshan HospitalEvaluation of Tumor Resectability Shall be Made in Consensus at Multidisciplinary Meetings, According to NCCN Guideline Version 1.2022 Pancreatic Adenocarcinoma, Patients With Non-metastatic Pancreatic Cancer

Start: 2023-06-01End: 2026-01-31Target: 92Updated: 2023-05-16

LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma

Active, not recruitingNCT06090162

Swiss Cancer InstituteNon-hodgkin Lymphoma, B Cell

Start: 2024-03-12End: 2026-12-01Target: 64Updated: 2026-03-30

Minimal Residual Disease in Solid Malignancies

Not yet recruitingNCT07268469

European Institute of OncologyBreast Cancer, Gastric Cancer, High Grade Serous Ovarian Cancer +2

Start: 2025-12-31End: 2033-07-31Target: 840Updated: 2025-12-05

Related Papers

Longitudinal circulating tumor DNA surveillance as predictor of progression in advanced non-small-cell lung cancer with long-term benefit to immunotherapy.

Journal of Clinical Oncology2026-05-28

Personalized tumor-informed circulating tumor DNA as predictor of progression risk after long-term responses to immunotherapy in advanced non-small-cell lung cancer.

Journal of Clinical Oncology2025-05-28

Undetectable circulating tumor DNA levels correlate with low risk of recurrence/metastasis in postoperative pathologic stage I lung adenocarcinoma patients.

2020-06-2016 citations

Circulating tumor DNA (ctDNA) analysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.

Journal of Clinical Oncology2020-05-202 citations

Circulating tumor DNA dynamics to predict cancer recurrence/metastasis in Chinese pathologic stage I lung adenocarcinoma.

Journal of Clinical Oncology2020-05-20